secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001104659-24-087876
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance updates corporate presentation; FY24 product revenue guidance $160-165M, Q2 revenue $31.1M
--------------------------------------------------------------------------------

- FY2024 product revenue guidance of $160-165 million; Q2 2024 net product revenue $31.1 million.
- Cash and investments ~$450 million as of July 24, 2024, after ~$200M ATM equity raise in Q2-Q3 2024.
- 51 Authorized Treatment Centers as of Aug 8, 2024; >225M patient lives covered; >55 patients treated.
- Pipeline: TILVANCE-301 Phase 3 frontline melanoma enrolling; IOV-LUN-202 NSCLC registrational data expected 2025.
- IOV-END-201 Phase 2 proof-of-concept trial in endometrial cancer initiated; IOV-4001 PD-1 inactivated TIL in Phase 1/2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924087876/0001104659-24-087876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924087876/tm2421344d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer